|

Neurobiological and Genomic Predictors of Relapse in Depression

RECRUITINGSponsored by Mehmet Kemal Arikan
Actively Recruiting
SponsorMehmet Kemal Arikan
Started2025-01-01
Est. completion2026-10-01
Eligibility
Age18 Years – 65 Years
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT07328373

Summary

The goal of this observational study is to test whether the discontinuation of antidepressant medications for patients with depression can be decided after the normalization of biological parameters. The main questions it aims are: 1. When patients with depression treated with antidepressants, does their brain activity also become normal? If so, 2. Then, can we stop the antidepressant treatment and expect minimum repeat of depression? The participants who receive a specific antidepressant treatment will be asked to: * Undergo quantitative electroencephalography (qEEG), * Record Event-related potential (ERP), * Record Sleep EEG * Answer Hamilton Depression Rating Scale question their psychiatrists asked * Give blood sample for genetic analysis * Repeat the above mentioned procedures for at least 3 times during their treatment period. Researchers will compare the results of patients with the results of healthy controls.

Eligibility

Age: 18 Years – 65 YearsHealthy volunteers accepted
Inclusion Criteria:

* Outpatients
* For patients, satisfying Major Depressive Disorder for Diagnostic and Statistical Manual of Mental Disorders (DSM-5-TR)
* Drug-free for at least 1-week

Exclusion Criteria:

* Any neurological and psychiatric comorbid conditions
* Hearing loss
* Physical diseases

Conditions3

DepressionHealthyMajor Depressive Disorder (MDD)

Browse More Trials

Depression trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.